Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Rises By 153.3%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 46,045 shares, a growth of 153.3% from the May 14th total of 18,181 shares. Based on an average daily volume of 130,709 shares, the short-interest ratio is currently 0.4 days. Approximately 1.8% of the company’s shares are short sold.

Institutional Trading of Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent quarter. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Trading Down 1.9%

Shares of Catheter Precision stock traded down $0.02 on Friday, hitting $1.05. The stock had a trading volume of 23,079 shares, compared to its average volume of 100,020. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. Catheter Precision has a one year low of $0.75 and a one year high of $8.50. The stock has a market cap of $2.82 million, a price-to-earnings ratio of -0.08 and a beta of -1.01. The stock’s 50-day simple moving average is $0.94 and its two-hundred day simple moving average is $1.52.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($20.90) by $19.51. The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $1.60 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.